Jazz Debt To Equity from 2010 to 2024

JAZZ Stock  USD 125.10  5.86  4.91%   
Jazz Pharmaceuticals Debt To Equity yearly trend continues to be fairly stable with very little volatility. Debt To Equity is likely to outpace its year average in 2024. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
1.5287521
Current Value
1.61
Quarterly Volatility
0.63473763
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 303.9 M, Other Operating Expenses of 3.4 B or Operating Income of 607.5 M, as well as many indicators such as Price To Sales Ratio of 1.93, Dividend Yield of 0.0 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Jazz Pharmaceuticals PLC over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Jazz Pharmaceuticals' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.12 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Jazz Debt To Equity Regression Statistics

Arithmetic Mean0.81
Coefficient Of Variation78.10
Mean Deviation0.49
Median0.58
Standard Deviation0.63
Sample Variance0.40
Range2.4778
R-Value0.80
Mean Square Error0.16
R-Squared0.64
Significance0.0003
Slope0.11
Total Sum of Squares5.64

Jazz Debt To Equity History

2024 1.61
2022 1.86
2021 1.53
2020 0.57
2019 0.52
2017 0.58
2016 1.08

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Debt To Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt To Equity 1.53  1.61 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.